NCT03462719 2026-04-13GLOWJanssen Research & Development, LLCPhase 3 Active not recruiting211 enrolled 23 charts
NCT03737981 2026-04-13Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic LeukemiaNational Cancer Institute (NCI)Phase 3 Active not recruiting465 enrolled 11 charts